We’re thrilled to announce a collaboration with Merck to evaluate the combination of SRF388 and KEYTRUDA®. This partnership will allow us to assess SRF388’s potential to deliver breakthrough therapies that can transform treatment for people with cancer: https://t.co/Gv7jmBeyew